Results 201 to 210 of about 70,073 (274)

Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel Setting. [PDF]

Oncol Ther
Ng K, Tyers BL, Ghose A, Kassamali A, El Debri R, Shamash J.   +5 more
europepmc   +1 more source

The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis. [PDF]

Hum Vaccin Immunother
Zhang F, Xiong Y, Luo Z, Xue Q, Wang L, Fu Q, Zhang W, Alisha PA, Okoli UA, Zhang G.   +9 more
europepmc   +1 more source

Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study. [PDF]

Int J Urol
Suzuki K, Khan N, Taguchi T, Hattori K, Chen G, Ghadessi M, Constantinovici N, Quintero V, Suzuki H.   +8 more
europepmc   +1 more source

Case Report: Deep and durable PSA response to same-agent enzalutamide rechallenge in metastatic castration-resistant prostate cancer without chemotherapy. [PDF]

Front Oncol
Chen H, Wang Y, Qu M, Gao X.
europepmc   +1 more source

Olaparib for Metastatic Castration-Resistant Prostate Cancer

New England Journal of Medicine, 2020
BACKGROUND Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with ...
Bivas, Biswas, Sandip, Ganguly, Joydeep, Ghosh   +2 more
openaire   +9 more sources

Some of the next articles are maybe not open access.

Related searches:

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.

NEJM Evidence, 2022
Abiraterone and Olaparib for Metastatic Prostate CancerPatients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair gene mutation status, received either abiraterone and olaparib or abiraterone and placebo ...
N. Clarke, A. Armstrong, A. Thiery-Vuillemin, M. Oya, N. Shore, E. Loredo, G. Procopio, Juliana de Menezes, G. Girotto, Ç. Arslan, N. Mehra, F. Parnis, E. Brown, F. Schlürmann, J. Joung, M. Sugimoto, J. Virizuela, U. Emmenegger, J. Navrátil, G. Buchschacher, C. Poehlein, E. Harrington, C. Desai, Jinyu Kang, F. Saad   +24 more
semanticscholar   +1 more source

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

The Lancet, 2021
BACKGROUND Lutetium-177 [177Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prostate-specific membrane antigen (PSMA), with activity and safety in patients with metastatic castration-resistant prostate ...
M. Hofman, L. Emmett, S. Sandhu, A. Iravani, A. Joshua, J. Goh, D. Pattison, T. Tan, I. Kirkwood, S. Ng, R. Francis, C. Gedye, N. Rutherford, A. Weickhardt, A. Scott, S. Lee, E. Kwan, A. Azad, S. Ramdave, A. Redfern, W. Macdonald, A. Guminski, E. Hsiao, W. Chua, P. Lin, A. Zhang, M. McJannett, M. Stockler, J. Violet, S. Williams, A. Martin, I. Davis   +31 more
semanticscholar   +1 more source

Castration-Resistant Prostate Cancer

Urologic Clinics of North America, 2017
Men with advanced prostate cancer are typically treated with hormonal therapy, which results in tumor shrinkage. However, tumors relapse and develop into a highly aggressive and lethal form of the disease, termed castration-resistant prostate cancer (CRPC).
Kelly Stratton, Michael Cookson
openaire   +2 more sources

Steroidogenesis in castration-resistant prostate cancer

Urologic Oncology: Seminars and Original Investigations, 2023
Castration resistance is in part attributable to aberrant activation of androgen receptor (AR) signaling by the intracrine activation of androgen precursors derived from adrenal glands. To overcome this, novel AR pathway inhibitors (ARPIs) that suppress androgen synthesis by CYP17 inhibition or AR activation by antiandrogen effects have been developed.
Masaki Shiota, Satoshi Endo, Leandro Blas, Naohiro Fujimoto, Masatoshi Eto   +4 more
openaire   +2 more sources